Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0006
Phoenix, Arizona, United States
Local Institution - 0034
Scottsdale, Arizona, United States
Local Institution - 0015
North Little Rock, Arkansas, United States
Local Institution - 0004
Bakersfield, California, United States
Local Institution - 0009
Sacramento, California, United States
Local Institution - 0022
San Diego, California, United States
Local Institution - 0030
Centennial, Colorado, United States
Local Institution - 0024
Washington D.C., District of Columbia, United States
Local Institution - 0027
Brandon, Florida, United States
Local Institution - 0016
Coral Gables, Florida, United States
Start Date
January 31, 2023
Primary Completion Date
August 23, 2024
Completion Date
May 29, 2025
Last Updated
September 10, 2025
180
ACTUAL participants
Deucravacitinib
DRUG
Placebo
OTHER
Lead Sponsor
Bristol-Myers Squibb
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions